Widely prescribed pain killers that provide relief with minimal side effects may have more pain-relieving properties than previously identified. A new study funded by the National Institute of Neurological Disorders and Stroke shows that non-steroidal anti-inflammatory drugs not only relieve pain at the local site of inflammation, but in fact affect the entire central nervous system.
Widely prescribed pain killers that provide relief with minimal side effects may have more pain-relieving properties than previously identified. A new study funded by the National Institute of Neurological Disorders and Stroke shows that non-steroidal anti-inflammatory drugs not only relieve pain at the local site of inflammation, but in fact affect the entire central nervous system.
NSAIDs reduce sensitivity of nerves in the central nervous system by inhibiting production of the COX-2 enzyme responsible for pain and inflammation.
A research team led by Clifford J. Woolf at Massachusetts General Hospital in Boston used an animal model to study COX-2's role in inflammatory pain. When inflammation occurred, researchers found COX-2 throughout the central nervous system, as well as at the local site of inflammation. They also found that inhibiting COX-2 production within the spinal cord and brain decreased pain and reduced hypersensitivity to normal sensations such as touch. Researchers now believe the widespread distribution of COX-2 within the central nervous system may contribute to the muscle and joint pain, depression, lethargy and loss of appetite that often occur with inflammation and infection.
"The findings indicate new treatment options for arthritis and other inflammatory pain conditions," said Cheryl A. Kitt, program director for pain research at the NINDS. "Targeting the central nervous system when using NSAIDs, rather than the specific peripheral pain site, may result in more effective pain relief." PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.